



Published in final edited form as:

Mayo Clin Proc. 2018 March ; 93(3): 307–320. doi:10.1016/j.mayocp.2017.10.023.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

A full list of authors and affiliations appears at the end of the article.

Abstract

Objective—To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival.

Patients and Methods—We conducted centralized immunohistochemical staining, semi-quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December 31, 2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than 12,000 person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4, and staining intensity was classified using a 2-tiered system for each marker (weak vs strong).

Results—Expression of MyD88 and TLR4 was similar in all histotypes except clear cell ovarian cancer, which showed reduced expression compared with other histotypes ($P<.001$ for both). In HGSOC, strong MyD88 expression was modestly associated with shortened overall survival (hazard ratio [HR], 1.13; 95% CI, 1.01–1.26; $P=.04$) but was also associated with advanced stage ($P<.001$). The expression of TLR4 was not associated with survival. In low-grade serous ovarian cancer (LGSOC), strong expression of both MyD88 and TLR4 was associated with favorable survival (HR [95% CI], 0.49 [0.29–0.84] and 0.44 [0.21–0.89], respectively; $P=.009$ and $P=.02$, respectively).

Conclusion—Results are consistent with an association between strong MyD88 staining and advanced stage and poorer survival in HGSOC and demonstrate correlation between strong MyD88 and TLR4 staining and improved survival in LGSOC, highlighting the biological differences between the 2 serous histotypes.

Epithelial ovarian cancer (EOC) remains the fifth leading cause of cancer death among women in United States, resulting in more than 14,000 estimated deaths in 2017.¹ Less than 40% of patients with EOC are cured, because more than 70% of patients are diagnosed with advanced disease (stage III or IV).² The frustrating truth is that since platinum-based treatment was introduced more than 30 years ago, the overall survival rate of women with

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Correspondence: Address to Ellen L. Goode, PhD, MPH, Department of Health Sciences Research, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (egoode@mayo.edu).

*David D. Bowtell, PhD; Georgia Chenevix-Trench, PhD; Anna de Fazio, PhD; Nadia Traficante, BSc; Sian Fereday, BSc, BA; and Jillian Hung, MHS; for the Australian Ovarian Cancer Study Group. Members of the Australian Ovarian Cancer Study Group are listed at the end of this article.

SUPPLEMENTAL ONLINE MATERIAL

Supplemental material can be found online at <http://www.mayoclinicproceedings.org>. Supplemental material attached to journal articles has not been edited, and the authors take responsibility for the accuracy of all data.

Potential Competing Interests: The authors report no competing interests.

EOC has changed little³; most patients will relapse and die from their disease despite response to first-line surgery and chemotherapy.⁴ Thus, novel therapeutic approaches for EOC are needed.⁵

The innate immune system recognizes the presence of bacterial pathogens through the expression of a family of membrane receptors known as Toll-like receptors (TLRs).⁶ Although their expression is well established in immune cells, TLRs are also found in a myriad of human cancers, including EOC.⁷ Among all the TLRs, Toll-like receptor 4 (TLR4) is perhaps the most extensively investigated.⁸ Cumulating studies have suggested that coexpression of TLR4, along with myeloid differentiation primary response gene 88 (MyD88), a TLR signaling adapter protein, associates with poor prognosis in EOC by facilitating proliferation, survival, and chemoresistance of EOC cells through the activation of various proinflammatory cytokines and antiapoptotic proteins.^{9–11} An additional report of atractylenolide-I, a novel TLR4-antagonizing agent, has been shown to sensitize EOC cells to paclitaxel by blocking the MyD88/TLR4 pathway.¹²

We previously analyzed immunohistochemical staining of MyD88 and TLR4 in a collection of approximately 450 EOC cases seen at Mayo Clinic; we found that the expression of both MyD88 and TLR4 was associated with poorer overall survival at $P < .05$.¹³ Although adjustment of clinical covariates such as age, stage, histology, grade, and surgical debulking status attenuated these results, MyD88- and TLR4-associated risk estimates remained suggestive and indicated the need for larger analyses.¹³

Therefore, we here report analysis of an independent EOC study population of more than 10 times the previous sample size, allowing for a more detailed assessment of prognosis by histotype with consideration of combined expression and clinical subsets.

PATIENTS AND METHODS

Eligible cases with primary diagnosis of epithelial ovarian, peritoneal, or fallopian tube cancer were diagnosed between January 1, 1978, and December 31, 2014, and enrolled into 21 collaborative studies participating in the Ovarian Tumor Tissue Analysis consortium.^{14–17} Mayo Clinic cases in the original report were not included.¹³ Histopathological classification for each case was provided by each contributing study, which was supplemented by additional pathologic review guided by WT1 and p53 IHC staining for most studies as described previously.¹⁴ From among 7377 cases arrayed on tissue microarrays (TMAs), we excluded those found to be duplicated across studies (n=4), missing vital status at last follow-up (n=288), missing time to last follow-up (n=17), missing age at diagnosis (n=11), found to be nonepithelial (n=63), missing tumor behavior (n=2), or unable to be scored for both markers because of inadequate amount of arrayed tumor tissue (n=1729) (Supplemental Figure, available online at <http://www.mayoclinicproceedings.org>). Thus, up to 5263 cases were used for analysis, including 4694 with tumors of the 5 major invasive histotypes (high-grade serous ovarian carcinoma [HGSOC]; endometrioid ovarian carcinoma [ENOC]; clear cell ovarian carcinoma [CCOC]; mucinous ovarian carcinoma [MOC]; and low-grade serous ovarian carcinoma [LGSOC]). As described below, additional cases were excluded for one marker or the other. Supplemental Table 1 (available online at

<http://www.mayoclinicproceedings.org>) presents characteristics of participating studies, including sample size, location, and data collection methods, and Supplemental Table 2 (available online at <http://www.mayoclinicproceedings.org>) presents clinical characteristics of analyzed cases.

Immunohistochemistry

Sections of TMAs were provided for centralized immunostaining at the Mayo Clinic, Rochester, Minnesota. For MyD88, the primary antibody was the rabbit polyclonal antibody NBP1-19785 (Novus Biologicals)¹⁸ and the detection system was Polymer Refine Detection System (Leica). This system included the hydrogen peroxidase block, postprimary and polymer reagent 3,3'-diaminobenzidine (DAB), and hematoxylin. Immunostaining visualization was achieved by incubating slides for 10 minutes in DAB and DAB buffer (1:19 mixture) from the Bond Polymer Refine Detection System. To this point, slides were rinsed between steps with 1' Bond Wash Buffer (Leica). Before and after DAB incubation, slides were rinsed in distilled water. For TLR4, the monoclonal antibody 3B6 (Novus Biologicals) was used as the primary detection antibody.¹⁹ The detection system was the Envision Flex System (Dako); the reagents were the Flex Peroxidase-Blocking for 5 minutes, Flex/HRP for 20 minutes, and Flex DAB+ Chromogen/Substrate Buffer (1 drop of DAB per 1 mL of substrate buffer) for 5 minutes. Slides were counterstained for 5 minutes using Schmidt hematoxylin and molecular biology grade water (1:1 mixture), followed by several rinses in 1' Bond wash buffer and distilled water; this is not the hematoxylin provided with the Refine kit. Once the immunohistochemistry processes were completed, slides were removed from the stainer and rinsed in tap water for 5 minutes. Slides were dehydrated in increasing concentrations of ethyl alcohol and cleared in 3 changes of xylene before permanent cover-slipping in xylene-based medium.

Scoring

Figure 1 shows representative stains with each score for MyD88 and TLR4. For MyD88, multiple cores from a subset of 312 cases were evaluated blindly by 2 independent pathologists (M.K. and P.R.) using a 4-tiered system (negative, weak, moderate, and strong), and a weighted kappa statistic was estimated. Then, differences in interpretation were discussed at a multiheaded microscope. Assessments of concordance in scores across these MyD88 cores indicated only modest levels of agreement (weighted κ , 0.55; 95% CI, 0.48–0.62); dichotomization of MyD88 expression into negative/weak and moderate/strong substantially increased agreement (κ , 0.81; 95% CI, 0.72–0.90). Because of this, all subsequent analyses of MyD88 and TLR4 expression used a dichotomous classification, henceforth referred to as weak (negative or weak expression) or strong (moderate or strong expression).

The cohort was subsequently split, with 51% of cases scored for MyD88 by M.K. and 49% by P.R. The TLR4 was evaluated by a single pathologist (M.K.). For cases with more than 1 scored core, the highest score was used in analysis. Because TMA cores with less than 25% epithelial tumor component were considered uninterpretable, a total of 137 cases were not scored for MyD88 (therefore, 5126 analyzed) and 676 cases were not scored for TLR4 (therefore, 4587 analyzed) (Supplemental Figure).

Analysis

Three sets of potential prognostic factors were evaluated: tumor expression of MyD88, of TLR4, and combinations of these 2. All statistical tests were 2-sided and uncorrected for multiple testing; all analyses were carried out using the SAS (SAS System, Inc) and R software (R Foundation for Statistical Computing) systems. Details on statistical analysis are provided in Supplemental Methods (available online at <http://www.mayoclinicproceedings.org>).

RESULTS

Clinical Characteristics of Study Cohort

The mean age at diagnosis for study participants was 58.0 years (Supplemental Table 2). Most of the cancers were advanced stage and high grade, and more than half of the patients were deceased as of last follow-up. Among the 5 main invasive EOC histotypes (N=4694), HGSOE was the most common (N=2865, 61%), followed by ENOC (N=670, 14%), CCOC (N=616, 13%), MOC (N=355, 7%), and LGSOC (N=188, 4%). Ten-year overall Kaplan-Meier survival estimates were 19% for HGSOE, 66% for ENOC, 50% for CCOC, 53% for MOC, and 30% for LGSOC.

Intracellular Distribution of Staining

The MyD88 staining distribution was mostly cytoplasmic with some membranous staining, consistent with the primarily cytoplasmic localization of the MyD88 adapter protein. Toll-like receptor 4 staining was distributed to both the cytoplasm and the plasma membrane. Toll-like receptor 4 is typically expressed both on the plasma membrane and in endosomes of myeloid leukocytes; localization of TLR4 expression on tumor cells has not previously been reported.

Distribution of Expression by Histotype

Distributions of MyD88 and TLR4 expression among the 5 most common invasive histotypes are presented in Table 1. In general, strong expression was more common than weak expression, with a notable exception: a minority of CCOCs (40%) showed strong TLR4 expression. Expression distributions for each marker were similar across HGSOEs, ENOCs, MOCs, and LGSOCs (68%–74% strong for MyD88; 71%–74% strong for TLR4). However, the expression in CCOCs was lower (only 59% strong for MyD88; only 40% strong for TLR4) compared with that of these histotypes combined (MyD88 $P<.001$; TLR, $P<.001$). Distributions among additional histopathological groups are provided in Supplemental Table 3 (available online at <http://www.mayoclinicproceedings.org>). Both MyD88 and TLR4 tended to be coexpressed, such that 67% of subjects either had low expression of both or high expression of both (χ^2 tests for independence $P<.001$, both overall and subset to the 5 most common invasive histotypes).

Clinical Correlates Among Women With HGSOE

Among women with HGSOE, associations of expression with clinical features are presented in Supplemental Table 4 (available online at <http://www.mayoclinicproceedings.org>).

Expression was similar regardless of age at diagnosis ($P=.65$ for MyD88 and $P=.12$ for TLR4). High-grade serous ovarian carcinomas with strong MyD88 expression were more likely to be advanced stage than those with weak MyD88 expression (82% vs 75%, $P<.001$). The expression of TLR4 did not differ by tumor stage ($P=.75$). Expression did not differ by extent of residual disease or known breast cancer susceptibility gene 1 (*BRCA1*) or breast cancer susceptibility gene 2 (*BRCA2*) pathogenic mutation.

Associations of Expression With Overall Survival by Histotype

Women with HGSOC and strong MyD88 expression had slightly poorer survival than did those with weak expression (unadjusted log-rank test $P<.001$; Figure 2). Results attenuated somewhat in age- and stage-adjusted Cox regression analyses but remained statistically significant (hazard ratio [HR], 1.13; 95% CI, 1.01–1.26; $P=.04$; Table 1). We found no evidence of a survival association with MyD88 expression for women with ENOC, CCOC, and MOC. Women with LGSOC and strong MyD88 expression had marginally better survival outcomes than did those with weak MyD88 expression (unadjusted log-rank test $P=.14$, Figure 2). This association strengthened after adjustment for study, age, and stage (Cox regression HR, 0.49; 95% CI, 0.29–0.84; $P=.009$; Table 1). Sensitivity analyses adjusting only for age and tumor stage demonstrated a similar protective effect of high MyD88 levels on survival (HR, 0.61; 95% CI, 0.39–0.97; $P=.04$).

For TLR4, even with nearly 12,000 years of follow-up for 2522 HGSOC cases (1737 deaths), we found no discernable evidence that survival differed by TLR4 expression. Kaplan-Meier curves overlapped considerably (Figure 3), and Cox regression analyses adjusting for age, stage, and study site were not statistically significant (HR, 1.06; 95% CI, 0.94–1.18; Table 1). There was some evidence for nonproportional hazards over time for women with HGSOC ($P=.01$). This can be seen in Figure 3, where the Kaplan-Meier curves cross in such a way that strong expression has a slight protective effect within the first 5 years of follow-up, then a slightly increased prognostic effect in years 5 through 10. However, in no instance is the difference between the 2 curves clinically meaningful. Moreover, time-stratified Cox regression analysis found no evidence of association with survival in either the first 5 years ($P=.37$) or the last 5 years of follow-up ($P=.80$).

We also did not observe any significant associations between TLR4 expression and overall survival for women with ENOC (Cox regression $P=.99$) or CCOC ($P=.76$) (Table 1). In univariate analyses, MOC tumors with strong TLR4 expression tended to fare better than those with weak expression (log-rank test $P<.001$; Figure 3). This association reversed direction in Cox regression analyses adjusting for study, age, and stage, such that MOC tumors with strong TLR4 expression fared more poorly than did those with weak expression, although the results failed to reach statistical significance (HR, 1.54; 95% CI, 0.91–2.60; $P=.11$; Table 1). Sensitivity analyses revealed that adjustment for study site had the most impact on this change in direction of association: analyses adjusting for age and tumor stage only were essentially null (HR, 1.01; 95% CI, 0.67–1.54; $P=.95$). Kaplan-Meier curves displayed some evidence of a survival advantage for patients with LGSOC with strong TLR4 expression compared to those with weak expression. This effect was even more pronounced and reached statistical significance in adjusted Cox regression analyses (HR for strong

expression compared with weak, 0.44; 95% CI, 0.21–0.89; $P=.02$; Table 1). As with MOC, analyses adjusting only for age and tumor stage were less striking (HR, 0.72; 95% CI, 0.43–1.20; $P=.21$).

Associations of Combined Expression With Overall Survival by Histotype

Because MyD88 and TLR4 coexpression has been shown to affect *in vitro* function,^{9–11} we examined associations between survival and combination of expression (Figure 4 and Table 2). For women with HGSOC, those with strong MyD88 expression had poorer survival than those with weak MyD88 expression, regardless of TLR4 expression. As with the uncombined analyses in Table 1, we found no discernable patterns with survival and combinations of MyD88 and TLR4 expression in women with ENOC or CCOC (Cox regression $P>.50$ for each). Consistent with the associations observed in uncombined analyses, we saw little or no separation of survival curves for MyD88 expression, regardless of TLR4 expression, and we saw some association between high TLR4 expression and survival regardless of MyD88 expression for MOC tumors ($P=.01$; Figure 4). Again, consistent with uncombined analyses, associations attenuated to nonsignificance after multivariate adjustment (Cox regression $P=.52$, Table 2). Compared with LGSOC tumors with weak expression of both markers, those with weak MyD88 and strong TLR4 expression (HR, 0.87; 95% CI, 0.28–2.71) and those with strong MyD88 and weak TLR4 expression (HR, 0.78; 95% CI, 0.28–2.21) had slightly longer survival. The LGSOC tumors with strong expression for both MyD88 and TLR4 had the longest survival times of the 4 expression groups (HR, 0.33; 95% CI, 0.13–0.85). We found no statistically significant survival interactions between MyD88 expression and TLR4 expression, either overall or by any of the histotypes in Table 1, indicating that effects of MyD88 expression on survival are not modified by expression of TLR4 and vice versa (interaction $P>.05$ for each).

Associations of Expression With Overall Survival in HGSOC Subsets

We evaluated the association between MyD88 and TLR4 expression and overall survival of HGSOCs by the extent of disease following surgery, *BRCA1* or *BRCA2* pathogenic mutation, and treatment (Table 3). For MyD88, the modest prognostic association remained; HRs were elevated in each group. For TLR4, there was a suggestion of effect modification by extent of residual disease (macroscopic disease: HR, 1.17; 95% CI, 0.98–1.39; $P=.084$; no macroscopic disease: HR, 0.76; 95% CI, 0.59–0.97; $P=.03$), but tests for interaction failed to reach statistical significance ($P=.13$). We also observed a potential prognostic association of TLR4 in *BRCA1* mutation carriers (HR, 2.69; 95% CI, 1.25–5.81; $P=.01$) and a potential protective effect in *BRCA2* carriers (HR, 0.26; 95% CI, 0.08–0.84; $P=.02$), but tests for interaction again failed to reach statistical significance ($P=.08$), perhaps due in part to small cell sizes within the mutation-positive groups. Combining MyD88 and TLR4 expression did not reveal additional patterns or interactions between the 2 expression values (Supplemental Table 5, available online at <http://www.mayoclinicproceedings.org>).

Additional Analyses

Because some previous ovarian cancer studies have combined LGSOC and HGSOC, we also analyzed invasive serous cases as a group, including those with missing grade. As expected, we found that combining the 2 groups together nullified the modestly higher expression-

related associations observed in HGSOCs and the strikingly lower risks observed in LGSOCs ($P=.21$ for MyD88 and $P=.49$ for TLR4; see Supplemental Table 6, available online at <http://www.mayoclinicproceedings.org>). Combining LGSOCs with 127 serous borderline tumors (a potential precursor lesion) resulted in a similar protective association with strong MyD88 and TLR4 expression levels that we had observed in LGSOC-only analyses. No discernable patterns were observed between expression (including combined) and survival (including interactions) in other histological groups (Supplemental Tables 6 and 7, available online at <http://www.mayoclinicproceedings.org>), although results for many of these should be interpreted with caution because of low sample sizes.

Last, among the 5 major histotypes, time to disease progression was known for approximately half the cases. Progression-free survival results were similar to overall survival results (Supplemental Tables 8 and 9, available online at <http://www.mayoclinicproceedings.org>). Note that the number of tests conducted is not small, no correction for multiple testing was done, and sample sizes are quite reduced in subset analyses.

DISCUSSION

Toll-like receptors, including TLR4, were originally described as myeloid leukocyte receptors for pathogen-associated molecular patterns, conserved structures present on subsets of pathogens but absent on normal host cells.²⁰ More recently, multiple endogenously expressed molecules (damage-associated molecular patterns) have been shown to stimulate myeloid cells via a TLR-dependent mechanism.²¹ Specifically, TLR4 has been demonstrated to be stimulated by hsp60, hsp70, hsp90B1, heparan sulfate, fibrinogen, HMGB1, BD-2, and additional endogenous molecules.²¹ Many of these damage-associated molecular patterns are present in the EOC microenvironment¹³ and could therefore drive intracellular signaling through MyD88 and TLR4 in EOC cells expressing these proteins. The ligation of TLR4 triggers recruitment of the adapter protein MyD88 to the receptor complex. Upon recruitment, MyD88, in turn, recruits the kinases IL-1 receptor-associated kinase 1 and receptor-associated kinase 4. Once active, receptor-associated kinase 1 and receptor-associated kinase 4 recruit TNF receptor-associated factor 6, which activates I κ B kinase. The activation of I κ B kinase causes degradation of inhibitor of kappa B, promoting nuclear translocation and signaling by nuclear factor kappa B.²² The signaling of nuclear factor kappa B generates proliferative and antiapoptotic signals in EOC cells.^{23,24}

We and others have previously suggested that MyD88 expression is associated with poorer survival in EOC.^{13,25} This association was confirmed in the present study only for patients with HGSOC, albeit with a relatively modest magnitude of effect after adjustment for age at diagnosis, disease stage, and study site. A likely explanation for the somewhat attenuated effect in the covariate-adjusted analysis is that MyD88 also is associated with advanced stage HGSOC. Thus, at least part of the impact of MyD88 on survival may be explained by its association with advanced disease. In sharp contrast with HGSOC, improved survival in LGSOC was associated with higher MyD88 expression. Furthermore, TLR4 expression also correlated positively with survival in LGSOC. Although the mechanism behind these divergent effects is not clear, the dichotomy of MyD88 and TLR4 associations between

HGSOC and LGSOC adds further evidence that these 2 histotypes are biologically distinct. Understudied LGSOCs need additional investigation. Another of the understudied histotypes, MOC, showed a nonsignificant association between TLR4 expression and prognosis, although this result was more pronounced before accounting for the effects of study site; consideration of similarities with gastrointestinal tumors may help to unravel its biology.²⁶

Although this study is the largest to examine the adaptor protein MyD88 and the pathogen-associated molecular pattern receptor TLR4, several significant limitations were unavoidable. First, the level of agreement between the 2 scorers for 4-scale MyD88 expression was modest, leading to the final analysis being performed on dichotomized data. A likely reason for the lower level of agreement with a 4-variable categorization is that the overall staining intensity of MyD88 was relatively modest. This change to a 2-variable categorization improved interscorer agreement but might limit the sensitivity of the analysis to detect subtle effects of MyD88 on survival. However, because this limitation would reduce sensitivity for detecting association between MyD88 staining intensity and survival, it would not be expected to contribute to false-discovery rate. We suggest that future studies consider other ways to measure MyD88 and TLR4 expression, perhaps by calculating the actual percent of cells positively stained.

CONCLUSION

The current study supports an association between increased MyD88 expression and poor survival in HGSOC and demonstrates that increased MyD88 expression is also associated with advanced stage HGSOC. In addition, the study suggests that both MyD88 expression and TLR4 expression are associated with favorable survival in LGSOC.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Matthew S. Block, MD, PhD, Robert A. Vierkant, MS, Peter F. Rambau, MD, Stacey J. Winham, PhD, Philipp Wagner, MD, Nadia Traficante, BSc, Aleksandra Tołoczko, MD, Daniel G. Tiezzi, MD, PhD, Florin Andrei Taran, MD, Peter Sinn, MD, PhD, Weiva Sieh, PhD, Raghwa Sharma, MBBS, FRCPA, Joseph H. Rothstein, MS, Teresa Ramón y Cajal, MD, Luis Paz-Ares, MD, Oleg Oszurek, MD, Sandra Orsulic, PhD, Roberta B. Ness, MD, MPH, Gregg Nelson, MD, PhD, Francesmary Modugno, PhD, Janusz Menkiszak, MD, PhD, Valerie McGuire, PhD, Bryan M. McCauley, BS, Marie Mack, PhD, Jan Lubinski, MD, PhD, Teri A. Longacre, MD, Zheng Li, MD, Jenny Lester, MPH, CCRP, Catherine J. Kennedy, BSc (Hons), Kimberly R. Kalli, PhD, Audrey Y. Jung, PhD, Sharon E. Johnatty, PhD, Mercedes Jimenez-Linan, MD, Allan Jensen, PhD, Maria P. Intermaggio, MS, Jillian Hung, MHS, Esther Herpel, MD, PhD, Brenda Y. Hernandez, PhD, MPH, Andreas D. Hartkopf, MD, Paul R. Harnett, MBBS, PhD, Prafull Ghatage, MD, José M. García-Bueno, MD, Bo Gao,

BMed, PhD, Sian Fereday, BSc, BA, Ursula Eilber, PhD, Robert P. Edwards, MD, Christiani B. de Sousa, MD, PhD, Jurandy M. de Andrade, MD, PhD, Anita Chudecka-Głaz, MD, PhD, Georgia Chenevix-Trench, PhD, Alicia Cazorla, MD, Sara Y. Brucker, MD, PhD, Australian Ovarian Cancer Study Group*, Jennifer Alsop, BA, Alice S. Whittmore, PhD, Helen Steed, MD, Annette Staebler, MD, Kirsten B. Moysich, PhD, Usha Menon, MD, Jennifer M. Koziak, BSc, Stefan Kommos, MD, Susanne K. Kjaer, MD, Linda E. Kelemen, ScD, Beth Y. Karlan, MD, David G. Huntsman, MD, Estrid Høgdall, PhD, Jacek Gronwald, MD, PhD, Marc T. Goodman, PhD, Blake Gilks, MD, María José García, PhD, Peter A. Fasching, MD, Anna de Fazio, PhD, Suha Deen, MBChB, Jenny Chang-Claude, PhD, Francisco J. Candido dos Reis, MD, PhD, Ian G. Campbell, PhD, James D. Brenton, MD, PhD, David D. Bowtell, PhD, Javier Benítez, PhD, Paul D.P. Pharoah, MD, PhD, Martin Köbel, MD, Susan J. Ramus, PhD, and Ellen L. Goode, PhD, MPH

Affiliations

Department of Medical Oncology (M.S.B., K.R.K.) and Department of Health Sciences Research (R.A.V., S.J.W., B.M.M., Z.L., E.L.G.), Mayo Clinic, Rochester, MN; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada (P.F.R., M.K.); Pathology Department, Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania (P.F.R.); Tübingen University Hospital, Department of Women's Health, Tübingen, Germany (P.W., F.A.T., A.D.H., S.Y.B., S.K.); Sir Peter MacCallum Department of Oncology, the University of Melbourne, Parkville, Victoria, Australia (N.T., D.D.B.); International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland (A.T., O.O., J. Lubinski, J.G.); Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil (D.G.T., C.B.S., J.M.A., F.J.C.R.); Department of Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (P.S.); Department of Population Health Science and Policy, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY (W.S., J.H.R.); Pathology West ICPMR Westmead, Westmead Hospital, the University of Sydney, Sydney, Australia (R.S.); University of Western Sydney at Westmead Hospital, Westmead, New South Wales, Australia (R.S.); Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain (T.R.C.); H12O-CNIO Lung Cancer Clinical Research Unit (L.P.-A.), and Oncology Department, Hospital Universitario 12 de Octubre (L.P.-A.), Madrid, Spain; Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (S.O., J. Lester, B.Y.K.); the University of Texas School of Public Health, Houston (R.B.N.); Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (G.N., P.G.); Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine (F.M., R.P.E.), Department of Epidemiology, University of Pittsburgh Graduate School of Public Health (F.M.), and Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute (F.M.), Pittsburgh, PA; Department of Gynecological

Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland (J.M., A.C.-G.); Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA (V.M.); Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK (M.M., J.A., P.D.P.P.); Department of Pathology, Stanford University, Stanford, CA (T.A.L.); Department of Gynecologic Oncology, the Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, China (Z.L.); Centre for Cancer Research, the Westmead Institute for Medical Research, the University of Sydney (C.J.K., J.H., P.R.H., B. Gao, A.deF.), and Department of Gynaecological Oncology, Westmead Hospital (C.J.K., J.H., A.deF.), Sydney, New South Wales, Australia; Division of Cancer Epidemiology, German Cancer Research Center (Deutsches Krebsforschungszentrum), Heidelberg, Germany (A.Y.J., U.E., J.C.-C.); Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia (S.E.J., G.C.-T.); Department of Histopathology, Addenbrookes Hospital, Cambridge, UK (M.J.-L.); Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (A.J., S.K.K.); School of Women's and Children's Health, University of New South Wales, Sydney, Australia (M.P.I., S.J.R.); Tissue Bank of the National Center for Tumor Diseases (NCT) Heidelberg (E. Herpel), and Institute of Pathology, University of Heidelberg (E. Herpel), Heidelberg, Germany; Cancer Center, University of Hawaii, Honolulu, HI (B.Y.H.); the Crown Princess Mary Cancer Centre, Westmead Hospital, the University of Sydney, Sydney, Australia (P.R.H., B. Gao); Oncology Department, Hospital General de Albacete, Madrid, Spain (J.M.G.-B.); Department of Cancer Genomics and Genetics, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia (S.F.); Pathology Department, Fundación Jiménez Díaz, Madrid, Spain (A.C.); Department of Health Research and Policy and Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA (A.S.W.); Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Royal Alexandra Hospital, Edmonton, Alberta, Canada (H.S.); Tübingen University Hospital, Institute of Pathology, Tübingen, Germany (A.S.); Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY (K.B.M.); Gynaecological Cancer Research Centre, Department of Women's Cancer, Institute for Women's Health, University College London, London, UK (U.M.); Alberta Health Services-Cancer Care, Calgary, Alberta, Canada (J.M.K.); Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (S.K.K.); Department of Public Health Sciences, Medical University of South Carolina and Hollings Cancer Center, Charleston, SC (L.E.K.); Department of Pathology and Laboratory Medicine, University of British Columbia (D.G.H.), and Centre for Translational and Applied Genomics, British Columbia Cancer Agency (D.G.H.), Vancouver, British Columbia, Canada; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark (E. Høgdall); Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (M.T.G.); Genetic Pathology Evaluation Centre, Vancouver General Hospital and University of British Columbia, Vancouver, British Columbia, Canada (B. Gilks); Human Genetics Group,

Spanish National Cancer Research Centre (Centro Nacional de Investigaciones Oncológicas) (M.J.G., J.B.), and Centre for Biomedical Network Research on Rare Diseases (Centro de Investigación Biomédica en Red de Enfermedades Raras), Instituto de Salud Carlos III (M.J.G., J.B.), Madrid, Spain; David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles (P.A.F.); University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany (P.A.F.); Department of Histopathology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK (S.D.); University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (J.C.-C.); Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre (I.G.C.), Sir Peter MacCallum Department of Oncology, University of Melbourne (I.G.C.), and Department of Pathology, University of Melbourne (I.G.C.), Melbourne, Victoria, Australia; Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre (J.D.B.), Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre (J.D.B.), and Cambridge Experimental Cancer Medicine Centre (J.D.B.), Cambridge, UK; Cancer Genomics Program, Research Department, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia (D.D.B.); the Garvan Institute, Sydney, New South Wales, Australia (D.D.B., S.J.R.); and Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK (P.D.P.P.)

Acknowledgments

We thank Mie Konno, Michelle Darago, Faye Chambers, and the Tom Baker Cancer Centre Translational Laboratories.

Grant Support: The work was supported by grant MOP-86727 from the Canadian Institutes for Health Research; grant 478416/2009-1 from the Brazilian National Council for Scientific and Technological Development; grant RS10-533 from the Calgary Laboratory Services Internal Research Competition; grant 01 GB 9401 from the German Federal Ministry of Education and Research of Germany; grants from the German Cancer Research Center (Deutsches Krebsforschungszentrum); grants K07-CA80668, P50-CA159981, and R01CA095023 from the US National Cancer Institute; grant MO1-RR000056 from the National Institutes of Health (NIH)/National Center for Research Resources/General Clinical Research Center; grant DAMD17-02-1-0669 from the US Army Medical Research and Materiel Command; grants R01-CA122443, P50-CA136393, P30-CA15083, U01-CA71966, U01-CA69417, R01-CA16056, and K07-CA143047 from the NIH; grants C490/A10119, C490/A10123, and C490/A16561 from Cancer Research UK; grants from the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge and at University College Hospital "Womens Health Theme"; grant SFB 685 from the NIH; grants from the Eve Appeal; grants from the Oak Foundation; grants from Deutsche Forschungsgemeinschaft; grant DAMD17-01-1-0729 (A.O.C.S.) from the US Army Medical Research and Materiel Command; grants from the Cancer Council Victoria; grants from Queensland Cancer Fund; grants from the Cancer Council New South Wales; grants from the Cancer Council South Australia; grants from the Cancer Foundation of Western Australia; grants from the Cancer Council Tasmania; grants ID400413 and ID400281 from the National Health and Medical Research Council of Australia; grants from the Peter MacCallum Cancer Foundation and Ovarian Cancer Australia (A.O.C.S.); enabling grants ID 310670 and ID 628903 (the Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group) from the National Health and Medical Research Council; grants 12/RIG/1-17 and 15/RIG/1-16 from the Cancer Institute NSW (the Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group); research grant R01-CA61107 (Malignant Ovarian Cancer Study) from the National Cancer Institute, Bethesda, MD; research grant 94 222 52 (MALOVA) from the Danish Cancer Society, Copenhagen, Denmark, and a grant (Malignant Ovarian Cancer Study) from the Mermaid I project; grant 15/TRC/1-01 (A.F. and P.R.H.) from the Cancer Institute NSW; grant SIOP-06-258-01-COUN (B.Y.K.) from the American Cancer Society Early Detection Professorship; and grant UL1TR000124 from the National Center for Advancing Translational Sciences (B.Y.K.).

Abbreviations and Acronyms

BRCA1	breast cancer susceptibility gene 1
BRCA2	breast cancer susceptibility gene 2
CCOC	clear cell ovarian carcinoma
DAB	3,3'-diaminobenzidine
ENOC	endometrioid ovarian carcinoma
EOC	epithelial ovarian cancer
HGSOC	high-grade serous ovarian carcinoma
HR	hazard ratio
LGSOC	low-grade serous ovarian carcinoma
MOC	mucinous ovarian carcinoma
MyD88	myeloid differentiation primary response gene 88
TMA	tissue microarray
TLR	Toll-like receptor
TLR4	Toll-like receptor 4

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin.* 2017; 67(1):7–30. [PubMed: 28055103]
2. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. *CA Cancer J Clin.* 2011; 61(3):183–203. [PubMed: 21521830]
3. Vaughan S, Coward JI, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. *Nat Rev Cancer.* 2011; 11(10):719–725. [PubMed: 21941283]
4. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. *Semin Oncol.* 2006; 33(2, Suppl 6):S3–S11.
5. Kandalaft LE, Powell DJ Jr, Singh N, Coukos G. Immunotherapy for ovarian cancer: what's next? *J Clin Oncol.* 2011; 29(7):925–933. [PubMed: 21079136]
6. De Nardo D. Toll-like receptors: activation, signalling and transcriptional modulation. *Cytokine.* 2015; 74(2):181–189. [PubMed: 25846205]
7. Muccioli M, Benencia F. Toll-like receptors in ovarian cancer as targets for immunotherapies. *Front Immunol.* 2014; 5:341. [PubMed: 25101083]
8. Mai CW, Kang YB, Pichika MR. Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. *Oncotargets Ther.* 2013; 6:1573–1587. [PubMed: 24235843]
9. Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. *Cancer Res.* 2006; 66(7):3859–3868. [PubMed: 16585214]
10. Szajnik M, Szczepanski MJ, Czystowska M, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. *Oncogene.* 2009; 28(49):4353–4363. [PubMed: 19826413]

11. Kim KH, Jo MS, Suh DS, et al. Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. *World J Surg Oncol*. 2012; 10:193. [PubMed: 22985132]
12. Huang JM, Zhang GN, Shi Y, et al. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. *Sci Rep*. 2014; 4:3840. [PubMed: 24452475]
13. Li Z, Block MS, Vierkant RA, et al. The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins. *Tumour Biol*. 2016; 37(10):13279–13286. [PubMed: 27460076]
14. Ovarian Tumor Tissue Analysis (OTTA) Consortium. Dose-response association of CD8+ tumor infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. *JAMA Oncol*. 2017; 3(12):e173290. [PubMed: 29049607]
15. Kobel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. *Histopathology*. 2014; 64(7):1004–1013. [PubMed: 24329781]
16. Kobel M, Kalloger SE, Lee S, et al. Ovarian Tumor Tissue Analysis consortium. Biomarker-based ovarian carcinoma typing: a histologic investigation in the Ovarian Tumor Tissue Analysis consortium. *Cancer Epidemiol Biomarkers Prev*. 2013; 22(10):1677–1686. [PubMed: 23880734]
17. Sieh W, Kobel M, Longacre TA, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. *Lancet Oncol*. 2013; 14(9):853–862. [PubMed: 23845225]
18. Mijares LA, Wangdi T, Sokol C, Homer R, Medzhitov R, Kazmierczak BI. Airway epithelial MyD88 restores control of *Pseudomonas aeruginosa* murine infection via an IL-1-dependent pathway. *J Immunol*. 2011; 186(12):7080–7088. [PubMed: 21572023]
19. Huhta H, Helminen O, Lehenkari PP, Saarnio J, Karttunen TJ, Kauppila JH. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma. *Oncotarget*. 2016; 7(17):23658–23667. [PubMed: 27008696]
20. Takeda K, Kaisho T, Akira S. Toll-like receptors. *Annu Rev Immunol*. 2003; 21(1):335–376. [PubMed: 12524386]
21. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. *J Cell Mol Med*. 2010; 14(11):2592–2603. [PubMed: 20629986]
22. Akira S. Toll-like receptor signaling. *J Biol Chem*. 2003; 278(40):38105–38108. [PubMed: 12893815]
23. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. *Oncogene*. 1999; 18(49):6853–6866. [PubMed: 10602461]
24. Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. *Cancer Res*. 2010; 70(10):4005–4014. [PubMed: 20424119]
25. d'Adhemar CJ, Spillane CD, Gallagher MF, et al. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. *PLoS One*. 2014; 9(6):e100816. [PubMed: 24977712]
26. Wang EL, Qian ZR, Nakasono M, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. *Br J Cancer*. 2010; 102(5):908–915. [PubMed: 20145615]

AUSTRALIAN OVARIAN CANCER STUDY GROUP

Management Group: D. Bowtell, Peter MacCallum Cancer Centre, East Melbourne, Department of Pathology, University of Melbourne, Parkville, Sir Peter MacCallum Cancer Centre, Department of Oncology, University of Melbourne, Parkville, and Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia, and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, England, UK; G. Chenevix-Trench, A. Green, and P. Webb, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; A.

DeFazio, Centre for Cancer Research, the Westmead Institute for Medical Research, the University of Sydney and Departments of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia; and D. Gertig, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia.

Project and Data Managers: N. Traficante and S. Fereday, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; S. Moore, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; J. Hung, Centre for Cancer Research, the Westmead Institute for Medical Research, the University of Sydney and Departments of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia; and K. Harrap, T. Sadkowsky, and N. Pandeya, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Research Nurses and Assistants: M. Malt, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; A. Mellon and R. Robertson, John Hunter Hospital, Lookout Road, New Lambton, New South Wales, Australia; T. Vanden Bergh, M. Jones, and P. Mackenzie, Royal Hospital for Women, Randwick, New South Wales, Australia; J. Maidens, Royal North Shore Hospital, St Leonards, New South Wales, Australia; K. Nattress, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Y.E. Chiew, A. Stenlake, and H. Sullivan, Centre for Cancer Research, the Westmead Institute for Medical Research, the University of Sydney and Departments of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia; B. Alexander, P. Ashover, S. Brown, T. Corrish, L. Green, L. Jackman, K. Ferguson, K. Martin, A. Martyn, and B. Ranieri, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; J. White, Royal Adelaide Hospital, Adelaide, South Australia, Australia; V. Jayde, Royal Hobart Hospital, Hobart, Tasmania, Australia; P. Mammers, Monash Medical Centre, Clayton, Victoria, Australia; L. Bowes, L. Galletta, D. Giles, J. Hendley, and K. Alsop, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; T. Schmidt and H. Shirley, Western Australian Research Tissue Network (WARTN), Osborne Park, Western Australia, Australia; C. Ball and C. Young, Women and Infant's Research Foundation, King Edward Memorial Hospital, Subiaco, Western Australia, Australia; S. Viduka, Hoa Tran, Sanela Bilic, and Lydia Glavinias, Western Australian Research Tissue Network (WARTN), Osborne Park, Western Australia, Australia; and Julia Brooks, St John of God Hospital, Western Australia, Australia.

Clinical and Scientific Collaborators: R. Stuart-Harris, Canberra Hospital, Garran, Australian Capitol Territory, Australia; F. Kirsten, Bankstown Cancer Centre, Bankstown Hospital, Bankstown, New South Wales, Australia; J. Rutovitz, Northern Haematology & Oncology Group, Integrated Cancer Centre, Wahroonga, New South Wales, Australia; P. Clingan and A. Glasgow, Illawarra Shoalhaven Local Health District, Wollongong Hospital, Wollongong, New South Wales, Australia; A. Proietto, S. Braye, and G. Otton, John Hunter Hospital, New Lambton, New South Wales, Australia; J. Shannon, Nepean Hospital, Kingswood, New South Wales, Australia; T. Bonaventura and J. Stewart, Newcastle Mater Misericordiae Hospital, Waratah, New South Wales, Australia; S. Begbie, Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia; M. Friedlander, Prince of Wales Clinical School, University of Sydney, New South Wales, Australia; D. Bell, S.

Baron-Hay, A. Ferrier (*deceased*), G. Gard, D. Nevell, N. Pavlakis, S. Valmadre, and B. Young, Royal North Shore Hospital, St Leonards, New South Wales, Australia; C. Camaris, R. Crouch, L. Edwards, N. Hacker, D. Marsden, and G. Robertson, Royal Hospital for Women, Randwick, New South Wales, Australia; P. Beale, J. Beith, J. Carter, C. Dalrymple, R. Houghton, and P. Russell, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; M. Links, St George Hospital, Kogarah, New South Wales, Australia; J. Grygiel, St Vincent's Hospital, Darlinghurst, New South Wales, Australia; J. Hill, Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia; A. Brand, K. Byth, R. Jaworski, and P. Harnett, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Sydney, New South Wales, Australia; R. Sharma, Department of Pathology, Westmead Clinical School, Westmead Hospital, the University of Sydney, New South Wales, Australia; G. Wain, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Sydney, New South Wales, Australia; B. Ward and D. Papadimos, Mater Misericordiae Hospital, South Brisbane, Queensland, Australia; A. Crandon, M. Cummings, K. Horwood, A. Obermair, L. Perrin, and D. Wyld, the Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; J. Nicklin, the Royal Brisbane and Women's Hospital, Butterfield Street, Herston, and Wesley Hospital, Auchenflower, Queensland, Australia; M. Davy, M.K. Oehler, C. Hall, and T. Dodd, Royal Adelaide Hospital, Adelaide, South Australia, Australia; T. Healy and K. Pittman, Burnside Hospital, Toorak Gardens, South Australia, Australia; D. Henderson, Flinders Medical Centre, Bedford Park, South Australia, Australia; J. Miller and J. Pierdes, Queen Elizabeth Hospital, Woodville South, South Australia, Australia; P. Blomfield, D. Challis, R. McIntosh, and A. Parker, Royal Hobart Hospital, Hobart, Tasmania, Australia; B. Brown and R. Rome, Freemasons Hospital, East Melbourne, Victoria, Australia; D. Allen, P. Grant, S. Hyde, R. Laurie, and M. Robbie, Mercy Hospital for Women, Heidelberg, Victoria, Australia; D. Healy, T. Jobling, T. Manolitsas, J. McNealage, P. Rogers, B. Susil, E. Sumithran, and I. Simpson, Monash Medical Centre, Clayton, Victoria, Australia; K. Phillips, D. Rischin, S. Fox, D. Johnson, S. Lade, M. Loughrey, N. O'Callaghan, and W. Murray, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; P. Waring, Department of Pathology, University of Melbourne, Parkville, Victoria, Australia; V. Billson, J. Pyman, D. Neesham, and M. Quinn, the Royal Women's Hospital, Parkville, Victoria, Australia; C. Underhill, Border Medical Oncology, Wodonga, Victoria, Australia; R. Bell, Andrew Love Cancer Centre, Geelong, Victoria, Australia; L.F. Ng, Ballarat Base Hospital, Ballarat, Victoria, Australia; R. Blum, Bendigo Health Care Group, Bendigo, Victoria, Australia; V. Ganju, Peninsula Health, Frankston, Victoria, Australia; I. Hammond, Y. Leung, and A. McCartney (*deceased*), Women and Infant's Research Foundation, King Edward Memorial Hospital, Subiaco, Western Australia, Australia; M. Buck, Mount Hospital, Perth, Western Australia, Australia; I. Haviv, Faculty of Medicine, Bar-Ilan University, Safed, Israel; D. Purdie and D. Whiteman, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; and N. Zeps, Western Australian Research Tissue Network (WARTN), St John of God Pathology, Osborne Park, Western Australia, Australia.




FIGURE 1. Representative immunohistochemical stains for MyD88 and TLR4 expression. A, High-grade serous carcinoma with weak MyD88 staining. B, High-grade serous carcinoma with weak TLR4 staining. C, High-grade serous carcinoma with strong MyD88 staining. D, High-grade serous carcinoma with strong TLR4 staining. MyD88 = myeloid differentiation primary response gene 88; TLR4 = Toll-like receptor 4.




FIGURE 2.

Kaplan-Meier overall survival plots by MyD88 expression for the 5 most common invasive ovarian cancer histotypes. A, High-grade serous ovarian cancer (N=2776); B, endometrioid ovarian cancer (N=660); C, clear cell ovarian cancer (N=608); D, mucinous ovarian cancer (N=345); and E, low-grade serous ovarian cancer (N=182). MyD88 = myeloid differentiation primary response gene 88.




FIGURE 3.

Kaplan-Meier overall survival plots by TLR4 expression for the 5 most common invasive ovarian cancer histotypes. A, High-grade serous ovarian cancer (N=2522); B, endometrioid ovarian cancer (N=612); C, clear cell ovarian cancer (N=561); D, mucinous ovarian cancer (N=303); and E, low-grade serous ovarian cancer (N=145). TLR4 = Toll-like receptor 4.




FIGURE 4. Kaplan-Meier overall survival plots by MyD88 and TLR4 expression for the 5 most common invasive ovarian cancer histotypes. A, High-grade serous ovarian cancer (N=2433); B, endometrioid ovarian cancer (N=602); C, clear cell ovarian cancer (N=293); D, mucinous ovarian cancer (N=553); and E, low-grade serous ovarian cancer (N=139). MyD88 = myeloid differentiation primary response gene 88; TLR4 = Toll-like receptor 4.

Associations of MyD88 and TLR4 Expression With Overall Survival Among Cases With the 5 Most Common Invasive Epithelial Ovarian Cancer Histotypes^{a,b}

TABLE 1

Histotype	Level	MyD88			TLR4			P
		Subjects, n (%)	No. of events	HR (95% CI)	Subjects, n (%)	No. of events	HR (95% CI)	
High-grade serous	Weak	712 (26)	450	Reference	734 (29)	490	Reference	.35
	Strong	2064 (74)	1426	1.13 (1.01–1.26)	1788 (71)	1247	1.06 (0.94–1.18)	
Endometrioid	Weak	213 (32)	58	Reference	169 (28)	48	Reference	.99
	Strong	447 (68)	109	0.96 (0.69–1.34)	443 (72)	105	1.00 (0.67–1.49)	
Clear cell	Weak	250 (41)	100	Reference	335 (60)	142	Reference	.76
	Strong	358 (59)	158	1.01 (0.77–1.32)	226 (40)	93	1.04 (0.79–1.38)	
Mucinous	Weak	96 (28)	36	Reference	79 (26)	40	Reference	.11
	Strong	249 (72)	96	1.12 (0.70–1.79)	224 (74)	71	1.54 (0.91–2.60)	
Low-grade serous	Weak	49 (27)	26	Reference	42 (29)	21	Reference	.02
	Strong	133 (73)	64	0.49 (0.29–0.84)	103 (71)	54	0.44 (0.21–0.89)	

^aHR = hazard ratio; MyD88 = myeloid differentiation primary response gene 88; TLR4 = Toll-like receptor 4.

^bAdjusted for study, age (continuous), and stage (I/II, III/IV, unknown).

TABLE 2
 Associations of Combinations of MyD88 and TLR4 Expression With Overall Survival Among Cases With the 5 Most Common Invasive Epithelial Ovarian Cancer Histotypes^{a,b}

Histotype	MyD88	TLR4	Subjects, n	No. of events	HR (95% CI)	P
High-grade serous	Weak	Weak	246	149	Reference	.10
		Strong	323	217	1.15 (0.92–1.42)	
	Strong	Weak	450	312	1.23 (1.01–1.51)	
		Strong	1414	991	1.25 (1.04–1.50)	
Endometrioid	Weak	Weak	85	22	Reference	.72
		Strong	103	27	1.18 (0.65–2.13)	
	Strong	Weak	75	23	1.40 (0.75–2.63)	
		Strong	339	78	1.08 (0.65–1.79)	
Clear cell	Weak	Weak	162	64	Reference	.82
		Strong	61	21	1.18 (0.70–1.99)	
	Strong	Weak	168	77	1.18 (0.82–1.69)	
		Strong	162	70	1.10 (0.76–1.60)	
Mucinous	Weak	Weak	28	14	Reference	.52
		Strong	43	13	1.73 (0.71–4.26)	
	Strong	Weak	44	23	1.05 (0.46–2.40)	
		Strong	178	57	1.43 (0.64–3.20)	
Low-grade serous	Weak	Weak	17	10	Reference	.02
		Strong	14	8	0.87 (0.28–2.71)	
	Strong	Weak	24	11	0.78 (0.28–2.21)	
		Strong	84	45	0.33 (0.13–0.85)	

^aHR = hazard ratio; MyD88 = myeloid differentiation primary response gene 88; TLR4 = Toll-like receptor 4.

^bAdjusted for study, age (continuous), and stage (II, III/IV, unknown). P values from unrounded 3 degree-of-freedom test.

TABLE 3

Associations of MyD88 and TLR4 Expression and Overall Survival Among HGSOC Cases by Extent of Residual Disease, by Pathogenic Mutation Status, and by First-Line Chemotherapy^{a,b}

Clinical attribute	MyD88				TLR4					
	Level	N	No. of events	HR (95% CI)	P	Level	N	No. of events	HR (95% CI)	P
Extent of residual disease										
Macroscopic disease	Weak	274	202	Reference	.45	Weak	292	219	Reference	.08
	Strong	800	659	1.07 (0.90–1.27)		Strong	687	576	1.17 (0.98–1.39)	
No macroscopic disease	Weak	185	92	Reference	.39	Weak	207	115	Reference	.03
	Strong	561	278	1.12 (0.87–1.44)		Strong	476	238	0.76 (0.59–0.97)	
Pathogenic mutation status										
Tested negative	Weak	152	90	Reference	.02	Weak	147	99	Reference	.16
	Strong	485	347	1.33 (1.04–1.70)		Strong	444	321	1.19 (0.94–1.51)	
Pathogenic <i>BRCA1</i> mutation	Weak	23	11	Reference	.70	Weak	27	10	Reference	.01
	Strong	82	50	1.18 (0.51–2.72)		Strong	71	43	2.69 (1.25–5.81)	
Pathogenic <i>BRCA2</i> mutation	Weak	13	4	Reference	.69	Weak	11	6	Reference	.02
	Strong	35	15	1.30 (0.36–4.71)		Strong	31	12	0.26 (0.08–0.84)	
First-line chemotherapy treatment										
Standard treatment	Weak	59	36	Reference	.27	Weak	102	62	Reference	.77
	Strong	280	176	1.24 (0.85–1.82)		Strong	231	150	0.96 (0.68–1.37)	

^a AUC = area under the concentration-time curve; *BRCA1* = breast cancer susceptibility gene 1; *BRCA2* = breast cancer susceptibility gene 2; HGSOC = high-grade serous ovarian cancer; HR, hazard ratio; MyD88 = myeloid differentiation primary response gene 88; TLR4 = Toll-like receptor 4.

^b Adjusted for study, age (continuous), and stage (I/II, III/IV, unknown); mutation status reflects results of germline testing; standard treatment includes patients receiving 4 cycles of intravenous carboplatin AUC 5 or 6 and paclitaxel 135 mg/m² or 175 mg/m² every 3 wk and patients receiving 4 cycles of intravenous carboplatin and paclitaxel every 3 wk with dose presumed to be carboplatin AUC 5 or 6 and paclitaxel 135 mg/m² or 175 mg/m².